Oura Acquires AI-Powered Primary Care Startup Counsel Health for $625 Million

2–3 minutes

Acquisition Overview

Oura announced on Tuesday that it is buying Counsel Health, an AI‑native primary‑care platform, for $625 million. The deal follows Oura’s decision to postpone its planned IPO—once expected to raise up to $2.2 billion—indefinitely, citing uncertainty in the IPO market.

Counsel Health Background

Counsel Health offers a chat‑based medical experience backed by licensed physicians and proprietary AI. Its service was integrated into the Oura app in June, allowing users to receive personalized medical advice and, when needed, connect with a physician—all within the same application.

The company raised a $25 million Series A round a year ago, led by Andreessen Horowitz (a16z) and GV. PitchBook estimates Counsel’s total fundraising at $36 million.

Strategic Rationale

While Oura has long dominated the smart‑ring market, competitors such as RingConn and Ultrahuman are gaining traction, pressuring Oura to innovate. By acquiring Counsel, Oura aims to broaden its ecosystem into preventative, acute, specialty, and chronic care, giving members actionable health insights beyond wearable data.

“Oura helps members understand their physiology and, with Counsel, they can take action on their health across a range of needs, from quick questions and prescriptions to lab results, chronic care, and referrals,” said Oura CEO Tom Hale in a press release.

Post‑Acquisition Plans and Leadership

Following the deal, Counsel will continue serving existing and new enterprise partners, with the goal of extending its AI‑native care model to a wider audience beyond Oura’s membership base.

Counsel CEO Muthu Alagappan will join Oura as chief clinical AI officer, and the company’s roughly 70 employees are expected to transition to Oura, according to Bloomberg. The transaction is slated to close before the end of 2027.

“At Counsel, we’ve built medical AI around trust, safety and responsibility, keeping physicians in the loop for clinical decisions,” Alagappan said in the press release. “Oura’s data gives clinicians objective context, trended biometrics, and member engagement to deliver more informed care. From the start, our teams bonded over a joint vision, shared culture, and mission, further solidifying as we negotiated our deal over the past few months.”

Financial Performance and Valuation

Oura reported quarterly revenue of $533 million for the period ending September 30, a 153 percent year‑over‑year increase. For fiscal year 2026, the company projects revenue of approximately $1.75 billion, reflecting 92 percent growth compared with the prior year.

In October 2025, Oura completed a $900 million late‑stage funding round, pushing its valuation to $11 billion.